November 5, 2025 - 19:07

Genelux Corporation has shared its financial results for the third quarter of 2025, highlighting significant advancements in its lung cancer programs. The company anticipates interim data updates for these programs to be available in the fourth quarter of 2025, showcasing its commitment to developing innovative treatments in the oncology space.
In addition to progress in lung cancer, Genelux is also preparing for the release of topline data from its OnPrime Phase 3 registrational trial focused on ovarian cancer. This crucial data is expected to be disclosed in the second half of 2026, marking a pivotal moment for the company as it aims to establish its presence in the competitive oncology market.
As of September 30, 2025, Genelux reported cash, cash equivalents, short-term investments, and restricted cash totaling $21.0 million. This financial position provides a solid foundation for the company as it advances its clinical programs and continues to seek innovative solutions for cancer treatment.
November 19, 2026 - 01:19
Skydance Unveils New Marketing Leadership Team Following Recent DealSkydance has announced its new marketing leadership team in the wake of the recent Paramount-WBD deal. In a memo from marketing chief Rebecca Mall, the company outlined the strategic direction and...
November 18, 2026 - 06:53
Executives Worry About Democratic Control in TexasA wave of concern has swept through Texas business circles as executives grapple with the implications of a potential Democratic takeover of the state`s executive branch. Many industry leaders fear...
November 17, 2026 - 20:26
Nvidia Posts Quarterly Earnings Amid Leadership ChangesNvidia released its first quarterly earnings report since Jensen Huang stepped down as CEO last week amid allegations of extramarital affairs. The earnings report revealed a mixed bag of results,...
November 17, 2026 - 02:27
Mastering the Algorithm: Key Insights for Business LeadersIn today`s fast-paced market, consumers are still the focal point for consumer packaged goods and retail brands. However, they are increasingly sharing the spotlight with algorithms. As artificial...